Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Lyell Immunopharma stock
Learn how to easily invest in Lyell Immunopharma stock.
Lyell Immunopharma is a biotechnology business based in the US. Lyell Immunopharma shares (LYEL) are listed on the NASDAQ and all prices are listed in US Dollars. Lyell Immunopharma employs 219 staff and has a trailing 12-month revenue of around $39.1 million.
How to buy Lyell Immunopharma stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – LYEL. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Lyell Immunopharma stock price (NASDAQ: LYEL)Use our graph to track the performance of LYEL stocks over time.
Lyell Immunopharma shares at a glance
|Latest market close||$3.28|
|52-week range||$2.74 - $8.74|
|50-day moving average||$3.62|
|200-day moving average||$5.45|
|Wall St. target price||$9.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$1.47|
Buy Lyell Immunopharma stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Lyell Immunopharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Lyell Immunopharma price performance over time
|1 week (2023-01-20)||9.70%|
|1 month (2022-12-28)||13.89%|
|3 months (2022-10-28)||-46.32%|
|6 months (2022-07-28)||-41.74%|
|1 year (2022-01-28)||-37.52%|
|2 years (2021-01-24)||N/A|
|3 years (2020-01-24)||N/A|
|5 years (2018-01-24)||N/A|
Is Lyell Immunopharma stock undervalued or overvalued?
Valuing Lyell Immunopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lyell Immunopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Lyell Immunopharma's P/E ratio
Lyell Immunopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Lyell Immunopharma shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Lyell Immunopharma's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Lyell Immunopharma financials
|Revenue TTM||$39.1 million|
|Gross profit TTM||$10.7 million|
|Return on assets TTM||-12.57%|
|Return on equity TTM||-28.61%|
|Market capitalisation||$795.3 million|
TTM: trailing 12 months
Lyell Immunopharma share dividends
We're not expecting Lyell Immunopharma to pay a dividend over the next 12 months.
Lyell Immunopharma overview
Lyell Immunopharma, Inc. , a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Lyell Immunopharma in the news
Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference
Frequently asked questionsWhat percentage of Lyell Immunopharma is owned by insiders or institutions?
Currently 15.74% of Lyell Immunopharma shares are held by insiders and 66.096% by institutions. How many people work for Lyell Immunopharma?
Latest data suggests 219 work at Lyell Immunopharma. When does the fiscal year end for Lyell Immunopharma?
Lyell Immunopharma's fiscal year ends in December. Where is Lyell Immunopharma based?
Lyell Immunopharma's address is: 201 Haskins Way, South San Francisco, CA, United States, 94080 What is Lyell Immunopharma's ISIN number?
Lyell Immunopharma's international securities identification number is: US55083R1041
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert